Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington’s disease for participants of varying functional disability: a pilot study

Andrew McGarry(Cooper Medical School of Rowan University), Ruin Moaddel(National Institute on Aging), Mohammed Khadeer(National Institutes of Health), Thomas N. Ferraro(Cooper Medical School of Rowan University), Cory Hackmyer(Cooper University Hospital), Basant Pradhan(Cooper University Hospital), John Gaughan(Cooper University Hospital), Irving W. Wainer(National Institute on Aging), Jacqueline Lovett(National Institutes of Health), Hamza Shaikh(Cooper University Hospital)
Scientific Reports
November 24, 2020
10.1038/s41598-020-77526-9
Cited by 38

Related Papers

Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead
|Neuroscience & Biobehavioral Reviews|2019|301
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
|Neurology|2016|137
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial
|The Lancet Neurology|2023|128
(R,S)-Ketamine Metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine Increase the Mammalian Target of Rapamycin Function
|Anesthesiology|2014|115
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
|The Lancet Neurology|2018|108